<DOC>
	<DOCNO>NCT01140646</DOCNO>
	<brief_summary>RATIONALE : S-adenosyl-L-methionine may help relieve hot flash woman base upon ability potentially modulate serotonin . PURPOSE : This phase II trial study side effect well s-adenosyl-L-methionine work treat hot flash woman history breast cancer wish take estrogen due perceive increased risk breast cancer .</brief_summary>
	<brief_title>Evaluation SAMe Hot Flashes</brief_title>
	<detailed_description>OBJECTIVES : I . To evaluate impact SAMe hot flash score woman history breast cancer woman wish take estrogen therapy fear increase risk breast cancer . II . To evaluate toxicity SAMe study population . III . To evaluate effect SAMe use quality-of-life ( QOL ) measure . OUTLINE : During first week , participant complete daily , prospective hot flash diary complete baseline questionnaire take study medication . After baseline week , participant receive oral s-adenosyl-L-methionine , 400 mg , daily day 8-14 twice daily day 15-49 absence unacceptable toxicity .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>Women history breast cancer ( currently without malignant disease ) woman history breast cancer wish avoid estrogen due perceive increased risk breast cancer Bothersome hot flash ( define occurrence &gt; = 14 time per week sufficient severity make patient desire therapeutic intervention ) Presence hot flash &gt; = 1 month prior registration Life expectancy &gt; = 6 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Ability complete questionnaire ( ) assistance Negative pregnancy test do = &lt; 7 day prior registration woman childbearing potential Any follow current ( = &lt; last 4 week ) plan therapy ( tamoxifen , raloxifene , aromatase inhibitor allow , patient must constant dose &gt; = 4 week must expect stop medication study period ) : antineoplastic chemotherapy , androgen , estrogen , progestational agent , herbal supplement , include soy , vitamin E , flaxseed , megadose vitamin ( herbal tea , multivitamin , vitamin D allow ) , warfarin ( 1 mg daily warfarin allow central line patency ) , medication interact SAMe ( antidepressant , monoamine oxidase ( MAO ) inhibitor , meperidine , dextromethorphan , pentazocine , tramadol , gabapentin , levodopa ) Pregnant woman Nursing woman Women childbearing potential unwilling employ adequate contraception Known allergy SAMe Current use use within past 6 month SAMe Clinically significant acute chronic progressive unstable neurologic , psychiatric , hepatic , renal , cardiovascular , respiratory , metabolic , systemic disease preclude participation study History bipolar disorder Parkinsonism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hot flash , dietary supplement , symptom management</keyword>
</DOC>